Novartis Pharmaceuticals Canada Announced Health Canada Grants Approval Of The Eye-tracking Neurological Assessment For Multiple Sclerosis For Use In Tracking Disease Progression In People Living With MS
Portfolio Pulse from Charles Gross
Health Canada has approved Innodem Neurosciences' Eye-Tracking Neurological Assessment for Multiple Sclerosis (ETNA™-MS), a class II software as a medical device (SaMD) for tracking disease progression in MS patients by providing an EDSS score between 1.0 and 4.5.
March 25, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis Pharmaceuticals Canada's collaboration with Innodem Neurosciences on ETNA™-MS, now approved by Health Canada, could enhance Novartis' portfolio in the MS treatment market.
The approval of ETNA™-MS by Health Canada, developed by Innodem Neurosciences and associated with Novartis Pharmaceuticals Canada, could potentially strengthen Novartis' position in the multiple sclerosis treatment market by offering a novel tool for disease progression tracking. This regulatory milestone may positively influence Novartis' stock in the short term as it highlights the company's commitment to advancing MS care and could lead to increased interest and adoption of the technology.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80